Tech Company Financing Transactions
Tigris Pharmaceuticals Funding Round
On 9/30/2010, Tigris Pharmaceuticals landed $6.5 million in Series C funding from private investors and Wexford Capital.
Transaction Overview
Company Name
Announced On
9/30/2010
Transaction Type
Venture Equity
Amount
$6,500,000
Round
Series C
Investors
Proceeds Purpose
Tigris intends to use the proceeds from the financing primarily to advance the development of its clinical product pipeline, including its lead compound, Aminoflavone pro-drug (AFP-464), a novel anticancer agent.
Company Information
Company Status
Out of Business
Industry
Biopharmaceutical
Mailing Address
3359 Woods Edge Circle 103
Bonita Springs, FL 34134
USA
Bonita Springs, FL 34134
USA
Phone
Website
Email Address
Overview
Tigris Pharmaceuticals, Inc. is a privately held biopharmaceutical company that develops therapeutic technologies to treat oncology, infectious diseases and other areas of unmet medical need. Tigris is currently conducting a Phase II clinical study for A-007, its topical treatment for pre-cancerous and cancerous anogenital lesions associated with HPV.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Edmundo Muniz
Chief Medical Officer
Joseph Pergolizzi
VP - Operations
Alexander Mironov
Browse more venture capital transactions:
Prev: 9/30/2010: Luminus Devices venture capital transaction
Next: 9/30/2010: Fab venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs